Cincinnati Children’s Chosen to Prepare Novel CAR‑T Therapy for Further U.S. Clinical Development
Post Date: March 12, 2026 | Publish Date:
Newly expanded Applied Gene and Cell Therapy Center selected by Tempest Therapeutics as its lead development and manufacturing partner
After reporting promising early clinical trial findings, a California-based biotech company is turning to the team at our Applied Gene and Cell Therapy Center to continue technology transfer and production work for an investigational dual‑targeting CAR‑T therapy called TPST-2003.
This novel treatment involves engineering a patient’s own immune cells to better recognize and kill cancer cells for people facing relapsed/refractory multiple myeloma (rrMM). The company recently announced promising interim findings from the ongoing REDEEM‑1 trial, where all six efficacy‑evaluable patients achieved complete responses.
As part of the new agreement, the Applied Gene and Cell Therapy Center will conduct the technology transfer and complete Investigational New Drug‑enabling manufacturing as Tempest prepares for a planned U.S. registrational study in late 2026.
Read more:
-
Full announcement from Tempest Therapeutics
-
Opening Our $60M State-of-the-Art Applied Gene and Cell Therapy Center
Don’t Miss a Post:
- Subscribe to the Research Horizons Newsletter
- Follow Cincinnati Children’s Research Foundation on Bluesky, X and LinkedIn
Latest Posts
About this blog
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment. Email researchnews@cchmc.org with questions or ideas.
Subscribe to Our Newsletter